Navigation Links
Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis

designed to evaluate the safety and efficacy of ACTEMRA plus methotrexate (4 mg/kg or 8 mg/kg) compared to placebo plus methotrexate in RA patients who had an inadequate response to anti-TNFs alone. Patients received either ACTEMRA intravenously (4 mg/kg or 8 mg/kg) every four weeks plus methotrexate weekly or placebo infusions every four weeks plus methotrexate weekly.

Data from the study were analyzed to determine patients' response to treatment by using three standard assessments: ACR score (1), developed by the of Rheumatology (ACR), DAS28 (2), a measurement of RA disease activity, and EULAR response criteria (3), a measurement of treatment response. The study included 498 patients at 128 trial sites in 13 countries, including the United States.

The RADIATE trial is one of five Phase III clinical studies designed to investigate ACTEMRA as a potential new treatment for RA. Roche and Chugai have initiated the collaborative clinical development program that has enrolled a total of more than 4,000 patients in 41 countries including the United States and several European countries.

About ACTEMRA (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody and represents a novel mechanism of action to treat RA. Studies suggest that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints. The global ACTEMRA Phase III clinical development program is designed to evaluate this clinical finding. The compound is not currently approved in the United States.

The most common adverse events reported in ACTEMRA global clinical studies are upper respiratory tract infections, headache, nasopharyngitis and hypertension. As with other biological disease modifying anti-rheumatic drugs (DMARDs), serious infections have been reported in some patients treated with ACTEMRA.

About Rheumatoid Arthritis

Rheumatoid arth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
2. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
3. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
4. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
5. One-Third of Patients Discontinue Common Breast Cancer Therapy
6. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:12/14/2009)... directors of Eli Lilly and Company (NYSE: ... quarter of 2010 of $0.49 a share on outstanding ... March 10, 2010 to shareholders of record at the ... ,, Lilly, a leading innovation-driven corporation, is developing a ... research from its own worldwide laboratories and from collaborations ...
(Date:12/14/2009)... -- Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on ... Conference Center in New York. 28th Annual ... Noon EST at the Westin St. Francis Hotel in ... will discuss Cardinal Health,s diverse products and services, company ...
(Date:12/14/2009)... Conn., Dec. 14 Zargis Medical Corp., ... SPDE ) and a spin-off from Siemens Corporate ... that it has begun selling its award-winning Zargis ... ,, Cardioscan and its accompanying Bluetooth®-enabled electronic stethoscope ... "2009 Innovation of the Year." ...
Breaking Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 1Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 2Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 3Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 4Sheller P C Law Firm Instrumental in Pfizers 242 3 Billion Settlement Today in Largest Pharmaceutical Whistleblower Case in History 56021 5eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 1eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 2MDS Announces Voting Support Agreements 56014 1MDS Announces Voting Support Agreements 56014 2MDS Announces Voting Support Agreements 56014 3
(Date:12/14/2009)... Pasierb, President ,, NEW YORK, Dec. 14 ... the Future study (MTF) -- the largest survey on ... 12th graders -- underscores that teens, intentional abuse of ... a cause for concern, with an alarming number of ... relatives. ,, Teen Abuse of Medication ...
(Date:12/14/2009)... SANTA ANA, Calif., Dec. 14 Grubb & Ellis ... directors has authorized a daily distribution to stockholders of record ... the period commencing on Jan. 1, 2010 and ending on ... on 365 days in the calendar year and will be ... a purchase price of $10.00 per share. These distributions ...
(Date:12/14/2009)... 14 On December 9, 2009, the United ... government,s position that private insurance companies are "plans" and ... Although other federal courts have held that contracts issued ... under Title 18 Section 1347, US vs. Frost ... has been held to be a "plan," because, as ...
(Date:12/14/2009)... had been treated, hadn,t spread, study finds , , MONDAY, ... the risk of death in male colon cancer survivors, ... 1986, included 668 men who,d been treated for stage ... had not spread (nonmetastatic cancer). Every two years, the ... new cancer and disease diagnoses, as well as their ...
(Date:12/14/2009)... is small and shouldn,t worry most users, researcher says ... who take antidepressants may have a small but statistically ... women not on the medications, a new study finds. ... significance," stressed Dr. Jordan W. Smoller, an associate professor ... of a report in the Dec. 14 issue of ...
Breaking Medicine News(10 mins):Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2009 Monitoring the Future Study Results 3Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 2Health News:Grubb & Ellis Healthcare REIT II Declares Initial Distribution 3Health News:Insurance Now Subject to Federal Jurisdiction 2Health News:Physical Activity May Prolong Survival After Colon Cancer 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... "Executive of the Year." , ... Birmingham, AL (PRWEB) ... International, and its CEO Jeffrey Tolbert took home two awards in ... Business Journal., , ,AirMed International was announced as the winner in ...
... follows nearly two-year ... delay in releasing data, WASHINGTON, Aug. ... Control and Prevention (CDC) increase,the estimate of new HIV infections in ... does not necessarily indicate an,ongoing increase in the annual estimated infection ...
... of lopinavir/ritonavir, study says , , FRIDAY, ... tazanavir/ritonavir (A/R) is as effective as twice-daily treatment ... starting antiretroviral treatment for the first time, a ... the researchers recommended once-daily A/R as a first-line ...
... study regarding Cognitive Behavioral Therapy as a treatment for Body Dysmorphic Disorder. ... into a crisis. BDD is similar to other disorders that respond ... thoughts on the study. , ... New York, NY (PRWEB) August 2, ...
... KNSY ) today announced that it will release ... ended June 30, 2008 at 7:00 A.M.,Eastern Time on ... CEO, will be hosting a teleconference,discussing the earnings results ... To participate in the teleconference call, dial 612-332-0345. ...
... the most aggressive types of brain tumor, have an ... a group of proteins known as receptor tyrosine kinases ... these RTK inhibitors have met with limited clinical success ... such treatment and most subsequently relapse after only a ...
Other Medicine News:Health News:Air Ambulance Company AirMed International Wins Multiple "Best in Business" Awards from Birmingham Business Journal 2Health News:New HIV Infection Figures from CDC Underscore Need for National AIDS Strategy for the U.S. 2Health News:Once-Daily Combo Works for New HIV Patients 2Health News:Has Hollywood's Diet Obsession Forced the US Government to Take Action? 2Health News:Has Hollywood's Diet Obsession Forced the US Government to Take Action? 3Health News:Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference 2
Swing-Arm™ Scatter Shield® provides lower extremity protection for personnel close to the tube. 24"Wx32"L lead shield swings 180 along table. Ideal for cardiac cath, special studies, electr...
Ball-and-socket center mount can rotate 360, allowing them to be turned hoirzontally, vertically, or at any angle. Very versatile! Available with or without torso placement contour cutout and in thre...
... Primarily designed to prevent lower body exposure ... used on any table where X-ray fluoroscopy is ... protection in applications where C-arm fluoroscopy units are ... are offered, each equipped with a 17 cm ...
Economy Apron, Excellent Protection, Value Priced...
Medicine Products: